Highlights BRAIN Biotech AG

Equities

BNN

DE0005203947

Market Closed - Xetra Other stock markets 11:36:29 2024-05-10 am EDT			5-day change	1st Jan Change
2.71 ^EUR	-1.45%		-2.52%	-25.96%

Apr. 16	Brain Biotech Plans Merger by Absorption of AnalytiCon Discovery	MT
Mar. 05	BRAIN Biotech AG and AMSilk GmbH Announce the Successful Completion of the First Phase of A Development Collaboration	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Brain Biotech Plans Merger by Absorption of AnalytiCon Discovery	Apr. 16	MT
BRAIN Biotech AG and AMSilk GmbH Announce the Successful Completion of the First Phase of A Development Collaboration	Mar. 05	CI
BRAIN Biotech AG Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 28	CI
BRAIN Biotech AG Reports Earnings Results for the Full Year Ended September 30, 2023	Jan. 17	CI
BRAIN Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-29	CI
BRAIN Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-25	CI
BRAIN Biotech to Look Acquisitions	23-05-24	CI
BRAIN Biotech AG acquired remaining 17.8% stake in Biocatalysts Limited for ?9.6 million.	23-05-23	CI
Resolutions of the Annual General Meeting 2023 on the Financial Year 2021/2022 of BRAIN Biotech AG	23-03-08	EQ
BRAIN Biotech AG Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-27	CI
Capital Markets Day 2023: BRAIN Biotech AG to build an international multi-niche enzyme and food ingredients champion	23-02-27	EQ
BRAIN Biotech AG with Strong Start into Fiscal Year 2022/23, 3M Reporting	23-02-27	EQ
BRAIN Biotech and TransCode Therapeutics join forces to develop a CRISPR-derived technology platform for cancer treatment	23-02-22	EQ
BRAIN Biotech Ends Contract with Roquette Frères on Natural Sweetener Joint Development	23-02-10	MT
BRAIN Biotech AG terminates contract for natural sweetener solution with Roquette Frères	23-02-10	EQ
BRAIN Biotech AG reports record figures in fiscal year 2021/22 − despite challenging geopolitical environment	23-01-16	EQ
BRAIN Biotech AG: BRAIN Group's Akribion Genomics business will prioritize the development of therapeutic applications within its CRISPR technology platform	23-01-10	EQ
BRAIN Biotech AG: prioritizing development of therapeutic applications of the Akribion Genomics technology platform (genome-editing)	23-01-10	EQ
BRAIN Biotech AG: Key Leadership Appointments at BRAIN Biotech AG, Zwingenberg Site	23-01-09	EQ
BRAIN Biotech AG Reports Earnings Results for the Full Year Ended September 30, 2022	22-11-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BRAIN Biotech AG

Equities

BNN

DE0005203947

Highlights

Filters